Bipolar disorder and adiposity: a study using whole body dual energy X-ray absorptiometry scans
Lana J Williams, Julie A Pasco, Felice N Jacka, Margaret J Henry, Seetal Dodd, Geoffrey C Nicholson, Mark A Kotowicz, Michael Berk
ACTA NEUROPSYCHIATRICA | WILEY-BLACKWELL | Published : 2011
Objective: Previous research has demonstrated a relationship between adiposity and bipolar disorder, although data are derived predominantly from patient samples and use indirect methods of assessing adiposity. This study investigated the association between bipolar disorder and several indices of adiposity, including body fat mass as measured by dual energy X-ray absorptiometry (DXA), in a community-based sample. Methods: In this study, 21 women with bipolar disorder and 523 healthy controls were drawn from an age-stratified, random, community-based sample of women (20-93 years) participating in the Geelong Osteoporosis Study. Bipolar disorder was diagnosed utilising a semi-structured clini..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council of Australia
The study was funded by the National Health and Medical Research Council of Australia (251638) and supported by an unrestricted educational grant from Eli Lilly. The funding bodies had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report and in the decision to submit the paper for publication.Lana Williams, Felice Jacka, Julie Pasco and Seetal Dodd have received research support from an unrestricted educational grant from Eli Lilly. Margaret Henry, Mark Kotowicz and Geoffrey Nicholson have no conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript. Michael Berk has received Grant/Research Support from the Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth.